202 related articles for article (PubMed ID: 26940474)
1. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
[TBL] [Abstract][Full Text] [Related]
2. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
3. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
4. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma.
Tsukagoshi M; Wada S; Yokobori T; Altan B; Ishii N; Watanabe A; Kubo N; Saito F; Araki K; Suzuki H; Hosouchi Y; Kuwano H
Cancer Sci; 2016 Feb; 107(2):116-22. PubMed ID: 26608587
[TBL] [Abstract][Full Text] [Related]
6. Proteasome regulation of ULBP1 transcription.
Butler JE; Moore MB; Presnell SR; Chan HW; Chalupny NJ; Lutz CT
J Immunol; 2009 May; 182(10):6600-9. PubMed ID: 19414815
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.
Duan X; Deng L; Chen X; Lu Y; Zhang Q; Zhang K; Hu Y; Zeng J; Sun W
Med Oncol; 2011 Jun; 28(2):466-74. PubMed ID: 20354827
[TBL] [Abstract][Full Text] [Related]
8. Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.
Ren J; Nie Y; Lv M; Shen S; Tang R; Xu Y; Hou Y; Zhao S; Wang T
Cell Mol Immunol; 2015 Nov; 12(6):768-76. PubMed ID: 25363527
[TBL] [Abstract][Full Text] [Related]
9. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells.
Nakajima NI; Niimi A; Isono M; Oike T; Sato H; Nakano T; Shibata A
Oncol Rep; 2017 Aug; 38(2):693-702. PubMed ID: 28677817
[TBL] [Abstract][Full Text] [Related]
11. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncotarget; 2019 Nov; 10(63):6805-6815. PubMed ID: 31827723
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
Son CH; Keum JH; Yang K; Nam J; Kim MJ; Kim SH; Kang CD; Oh SO; Kim CD; Park YS; Bae J
Radiat Oncol; 2014 Feb; 9():49. PubMed ID: 24512718
[TBL] [Abstract][Full Text] [Related]
14. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy.
Chen Y; Lin G; Guo ZQ; Zhou ZF; He ZY; Ye YB
PLoS One; 2013; 8(7):e69044. PubMed ID: 23935919
[TBL] [Abstract][Full Text] [Related]
15. ATM protein is deficient in over 40% of lung adenocarcinomas.
Villaruz LC; Jones H; Dacic S; Abberbock S; Kurland BF; Stabile LP; Siegfried JM; Conrads TP; Smith NR; O'Connor MJ; Pierce AJ; Bakkenist CJ
Oncotarget; 2016 Sep; 7(36):57714-57725. PubMed ID: 27259260
[TBL] [Abstract][Full Text] [Related]
16. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
17. Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.
Luis Espinoza J; Takami A; Trung LQ; Nakao S
Cancer Sci; 2013 Jun; 104(6):657-62. PubMed ID: 23445485
[TBL] [Abstract][Full Text] [Related]
18. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.
Andresen L; Skovbakke SL; Persson G; Hagemann-Jensen M; Hansen KA; Jensen H; Skov S
J Immunol; 2012 Feb; 188(4):1847-55. PubMed ID: 22227571
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
20. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
